Stock Market Bristol Myers to pay up to $1.38 billion to...

Bristol Myers to pay up to $1.38 billion to develop, sell Agenus’s cancer therapy By Reuters


- Advertisment -

© Reuters. The logo of U.S. drugmaker Bristol Myers Squibb. via REUTERS

(Reuters) – Drugmaker Bristol Myers (NYSE:) Squibb will pay biotech firm Agenus (NASDAQ:) Inc up to $1.38 billion to exclusively develop and commercialize its experimental cancer drug, AGEN1777, the companies said on Tuesday.

The drug candidate, primarily being tested to improve anti-tumor activity, will also be studied and developed by Bristol Myers for immuno-oncology treatments including non-small cell lung cancer, which accounts for about 85% of lung cancer cases globally.

Bristol Myers has been betting on sales of its Opdivo drug to treat such cancers, but that market is currently dominated by Merck & Co’s rival treatment Keytruda.

Agenus will receive up to $1.36 billion in development, regulatory and commercial milestones in addition to double-digit royalties on net product sales. It will receive an upfront payment of $200 million. (

The biotech company will retain options to conduct clinical studies under the development plan, and to test it in combination with certain other pipeline assets, and will co-promote AGEN1777 in the United States after commercialization.

Agenus plans to file application to begin human trials for the therapy with the U.S. Food and Drug Administration in the second quarter of this year, the company said.

(This story corrects to “application to begin human trials” from “marketing application” in last paragraph)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Latest news

Argentina averts default in debt deal with Paris Club

Argentina has reached a deal to avoid another damaging default by delaying the bulk of a $2.4bn payment due...

Stocks making the biggest moves in the premarket: GameStop, MicroVision, Sanderson Farms & more

Take a look at some of the biggest movers in the premarket:GameStop (GME) – The videogame retailer's stock jumped...

Morgan Stanley will bar workers without Covid vaccinations from most New York offices beginning July 12

Morgan Stanley on Tuesday told its staff that workers and clients who are not vaccinated against Covid-19 will be...
- Advertisement -

Partner Colorado Credit Union names next CEO

Partner Colorado Credit Union in Arvada, Colorado, named Doug Fagan as its next president and CEO.Fagan is succeeding Sundie...

How the Surgery Center of Oklahoma Tapped the Cash Market | G. Keith Smith, MD

G. Keith Smith, MDDr. G. Keith Smith is a board-certified anesthesiologist...

Must read

- Advertisement -

You might also likeRELATED
Recommended to you